0001415889-24-001313.txt : 20240117 0001415889-24-001313.hdr.sgml : 20240117 20240117164828 ACCESSION NUMBER: 0001415889-24-001313 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240116 FILED AS OF DATE: 20240117 DATE AS OF CHANGE: 20240117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thye Dirk CENTRAL INDEX KEY: 0001638945 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 24539052 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quince Therapeutics, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD., SUITE 273 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cortexyme, Inc. DATE OF NAME CHANGE: 20160104 4 1 form4-01172024_090120.xml X0508 4 2024-01-16 0001662774 Quince Therapeutics, Inc. QNCX 0001638945 Thye Dirk C/O QUINCE THERAPEUTICS, INC. 601 GATEWAY BLVD, #1250 SOUTH SAN FRANCISCO CA 94080 true true false false CHIEF EXECUTIVE OFFICER 0 Common Stock 2024-01-16 4 M 0 90531 0.55 A 539442 D Common Stock 2024-01-16 4 M 0 149999 0.94 A 689441 D Employee Stock Option (right to buy) 0.55 2024-01-16 4 M 0 90531 0 D 2022-03-27 Common Stock 90531 115860 D Employee Stock Option (right to buy) 0.94 2024-01-16 4 M 0 149999 0 D 2033-01-31 Common Stock 149999 450001 D The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years. The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. /s/ Dirk Thye 2024-01-17